Other News To Note
Tuesday, June 21, 2011
Prometheus Laboratories Inc., of San Diego, will defend its method patents in the Supreme Court for calibrating the proper dosage of thiopurine drugs used to treat autoimmune diseases. The court agreed Monday to hear Mayo Collective Services v. Prometheus Laboratories Inc. The first time the case came before the high court, the justices sent it back to the U.S. Court of Appeals for the Federal Circuit with instructions to reconsider it in light of the Bilski v. Kappos ruling. The Federal Circuit maintained that Prometheus' personalized medicine-type claims are patent-eligible.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.